ArticleCurrent medical science2025
Data Mining of Adverse Reactions to Iodinated Contrast Media Based on a Municipal Spontaneous Reporting System in China.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance analysis of iodinated contrast media related respiratory adverse effects based on the FDA adverse event reporting system.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIodinated contrast media (ICM) are widely used in medical imaging, particularly in computed tomography (CT) and magnetic resonance imaging (MRI) examinations, to increase image quality and improve diagnostic accuracy. Despite their clinical utility, ICM are associated with various adverse drug reactions (ADRs), including allergic reactions and other systemic effects. This study aimed to evaluate ICM-related ADRs through the Chinese spontaneous reporting system (SRS) and provide reference information for clinical practice.
methodsWe analyzed ADRs related to ICM on the basis of data from the SRS in Wuhan, China, from January 1, 2018, to December 31, 2023.
resultsA total of 2,166 ADR reports related to four ICM (iodixanol, iohexol, ioversol, and iomeprol) were analyzed to assess the proportion and severity of adverse reactions. The results revealed that the majority of the ADRs were mild, with the most common symptoms being rash (54.76%) and itching (35.18%). Gastrointestinal and respiratory symptoms were also noted, although less frequently. Anaphylactic shock was documented in 48 patients, accounting for 9.69% of severe adverse reactions. The incidence of ADRs was greater in summer. Circulatory system diseases were the most prevalent underlying conditions in patients who experienced ADRs. Treatment primarily involved symptomatic management, including corticosteroids and antihistamines, with adrenaline administered in severe cases.
conclusionsThis study highlights the importance of monitoring high-risk patients, especially elderly patients and those with preexisting conditions, and underscores the need for timely intervention in severe reactions. Future prospective studies are necessary to facilitate the selection of more appropriate ICM for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.